



European Monitoring Centre  
for Drugs and Drug Addiction

# Most recent data, analyses and feed-back from the '2016 DRID national updates'


Eleni Kalamara, Dagmar Hedrich, Linda Montanari,  
Isabelle Giraudon

15-16 June 2017, Lisbon

DRID/TDI annual expert meeting



## DRID among PWID in Europe




### Structure of the presentation

- Latest HIV situation
- Hepatitis C and B
- DRID in prisons
- DRID prevention




# Newly diagnosed HIV cases related to injecting drug use

EU average: 2.4 cases/million population



## HIV Risk Assessment (RA) indicators

- HIV-related indicators
- Indicators of transmission risk among PWID
- OST and NS coverage indicators



Country	HIV-related indicators	
	HIV cases	HIV prevalence trend
Austria	Green	Green
Belgium*	Green	Green
<b>Bulgaria*</b>	Green	Red
Croatia	Green	Green
Cyprus	Green	Green
Czech Republic	Green	Green
Denmark	Green	Green
<b>Estonia*</b>	Green	Red
Finland*	Green	Green
France	Green	Green
<b>Germany</b>	Yellow	Green
<b>Greece*</b>	Yellow	Red
Hungary*	Green	Green
<b>Ireland*</b>	Yellow	Green
Italy	Green	Green
<b>Latvia</b>	Green	Red
<b>Lithuania</b>	Green	Red
<b>Luxembourg*</b>	Green	Red
Malta	Green	Green
Netherlands	Green	Green
Norway*	Green	Green
Poland	Green	Green
Portugal	Green	Green
<b>Romania*</b>	Yellow	Green
Slovakia	Green	Green
Slovenia*	Green	Green
Spain*	Green	Green
Sweden	Green	Green
Turkey*	Green	Green
United Kingdom*	Green	Green





3

## DRID situation, Baltic countries (EE)



### EE. SP study in Kohtla-Jarve, 2016




4

## DRID situation, Baltic countries (LV)




LV. SP study in multiple cities, 2014



## DRID situation, Baltic countries (LT)




LT. SP study in 3 cities, 2014



## On-going HIV epidemics/alerts (LU)



LU



- Enhance HR (i.e NS exchange)
- Targeted outreach programs
- Epidemiological studies

- Cocaine
- High frequency
- Highly marginalised
- Increased proportion of drug use related prostitution




| 7

## Other on-going HIV epidemics/ issues identified

### ■ HIV outbreak in IE

Number of new HIV cases among PWID, by year of diagnosis, reported in Ireland, 1990–2015



Injecting a – PVP by homeless DUs

Reusing needles/syringes

Having sex with PWID

Source: IE WB 2016, Unpublished data reported to Department of Health by National Disease Surveillance Centre and HPSC.

- **HIV outbreak in Glasgow** (47 cases in 2015, evidence of recent infection in 2017)  
Homeless. Injecting psychoactive drugs, mainly heroin.  
Injecting in public places, in and around Glasgow city centre.
- **Increase in HIV new cases among PWID in Bavaria, Munich**  
Injecting NPS, particularly synthetic cathinones/ legal highs




| 8

## HIV situation among PWIDs in GR and RO



**GR:**  
HIV incidence **dropped** from **7.8 to 1.7** cases per 100pyrs between 2012 and 2013 (1)


New HIV cases per million pop, GR and RO



**RO:**

- 15% of new HIV cases attributed to IDUs in 2016
- Late diagnosis (CD4<100 cells/mm3 in half of the HIV cases among IDUs)


No of syringes distributed, GR and RO



1. Sypsa V, Psychogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, et al. (2017) Rapid decline in HIV incidence among persons who inject drugs during a fast-track combination prevention program after an HIV outbreak in Athens. The Journal of Infectious Diseases doi: 10.1093/infdis/jix100.

## HCV antibody/ HBsAg among injecting drug users

Prevalence of HCV antibody and HBV surface antigen among injecting drug users, 2014/15



**HCV:**

- 24 countries with data in 2015-16 (13 national)
- Range from 16%-84% among national samples
- Prevalence >50% in 5 out of 13 countries with national data
- 3 countries with s.s increase (GR, HU, SI) between 2010-2015

**HBsAg:**


- 16 countries with data in 2015-16 (7 national)
- Range from ~3%-11% among national samples



Source: EDR 2017

## HCV antibody/ HBsAg among injecting drug users: Where do we get the data from?


- **Study design:**  
**Mainly DT**  
 13 countries with sero-prevalent studies (3 national)
- **Specimen:**  
**Mainly serum**  
 18/24 countries serum and 5 DBS
- **Settings:**  
**Mainly DTC (16/24) & NSP (12/24)**
- **Trends**  
 (17/24) and 7/13 SP studies
- **Sample sizes**  
**National:** 52 - 9080 (3/13 <100)  
**Subnational:** 20 - 2631
- **HCV – RNA data:**  
 Sparse data (5 countries since 2010)



Source: EDR & SB 2017

## HCV antibody/ HBsAg among injecting drug users by age group

Prevalence of hepatitis C infection among injecting drug users (%)




Sample sizes <10 are excluded



# HCV antibody/ HBsAg among injecting drug users by years of injection

Prevalence of hepatitis C infection among injecting drug users (%) <2yrs >10yrs




# DRID in prisons

## DRID epidemiology in prisons

- **Not many studies**  
(6 countries in 2006/15, 3 in 2016/17)
- **HIV** : 0% - 18%
- **HCV**: 12% - 97%
- **Odds of infection higher in people ever in prison**

Association between prior prison history and HCV infection among PWID in Europe, 2006-2015



## Interventions for infectious diseases/ other harm reduction interventions

(source: Prisons WB 2016, L. Montanary, Joint EMCDDA-ECDC meeting 2017)


Type of Interventions	N. countries
Mainly information to prisoners and staff	All
Infectious diseases testing offered (anonymous and voluntary) in most countries (HBV, HCV, HIV, TBC)	26
Vaccination for Hepatitis B	12
Treatment for Hepatitis C	
Treatment for HIV	
Needle and Syringes Pro	
Condom distribution	
Distribution of other materials	

• Diverse responses in place, although availability is still scarce

• Particularly limited availability for some harm reduction interventions


# Harm reduction coverage

Coverage of specialised syringe programmes: number of syringes provided per estimated injecting drug user



NB: Data displayed as point estimates and uncertainty intervals.


Density of NS services (% of NUTS II/III with NS services)



15

# Percentage of high-risk opioid users receiving opioid substitution treatment, 2015

Coverage of opioid substitution treatment (percentage of estimated high-risk opioid users receiving the intervention)



Source: EDR 2017

16





**Again,  
a big thanks to all of you for  
your input and  
collaboration**